ADX-47273

(S)-(4-fluorophenyl)(3-(3-(4-fluorophenyl)-1, 2, 4-oxadiazol-5-yl)piperidin-1-yl)methanone

0.17 uM [1], 0.17 uM [1], 0.17 uM [1], 0.17 uM [1], 0.17 uM [1], 0.17 uM [1]

ADX47273 intraperitoneally administrated at dose of 10 mg/kg increases ERK and CREB phosphorylation in both the prefrontal cortex and hippocampus in Long-Evans rats. ADX47273 intraperitoneally administrated at dose of 10–100 mg/kg produces dose-dependent decreases in avoidance responding and increased escapes at doses that did not produce any response failures in Sprague-Dawley rats. ADX47273 intraperitoneally administrated at dose of 10–300 mg/kg produces a dose-dependent decrease in apomorphine-induced climbing in CF-1 mice. ADX47273 intraperitoneally administrated at dose of 100 mg/kg decreased locomotor activity compared with vehicle pretreatment at 20 min after PCP, 30 min after apomorphine, and at all time points after amphetamine challenge in mice. ADX47273 intraperitoneally administrated at dose of 175 mg/kg lowers dopamine levels in the Sprague-Dawley rat nucleus accumbens. ADX47273 intraperitoneally administrated at dose of 1 to 50 mg/kg increases novel object recognition and reduces impulsivit the five-choice serial reaction time test in rats. [1] ADX47273 intraperitoneally administrated at dose of 100 mg/kg signi cantly decreases conditioned avoidance response at 30 and 90 min post-injection in male Sprague–Dawley rats. [3]

ADX-47273 Chemical Structure

2 years -20CPowder, 2 weeks4Cin DMSO, 2 months-80Cin DMSO